细胞增殖标志物帮助胃癌诊断和预后判断

近日，上海交通大学医学院附属瑞金医院于颖彦、朱正刚等研究发现，一种在胃癌患者中表达上调的细胞增殖标志物(IPO—38)可作为胃癌诊断与患者预后判断的标志物。该研究结果于2008年8月5日在线发表于《蛋白组学研究杂志》（J Proteome Res）。

胃癌等腹腔器官肿瘤具有发病隐匿的特点。尽管目前一些肿瘤标志物已被应用于腹腔肿瘤的辅助诊断，但由于敏感性与特异性均不理想，无法满足临床应用的要求。研究人员利用血清抗体芯片、蛋白质免疫沉淀以及质谱鉴定等技术，通过体外试验以及大量临床病例分析发现，血清IPO—38水平在胃癌患者中升高，以此为胃癌诊断的标志物，可以将诊断敏感性从原来使用传统标志物时的不足30%提高到57.4%，可以使诊断的特异性超过90%，对判断胃癌患者的临床预后也具有良好的应用价值。同时，研究人员阐明了IPO—38血清抗原的化学本质为核小体组蛋白类抗原，为今后深入研究胃癌临床转归与转移机制提供了新线索。

血清样本比肿瘤组织样本易获得、采样创伤性小、检测结果可反映全身情况。该基础研究成果快速转化为临床诊断方法，已获得国家发明专利。据悉，该方法是针对中、晚期胃癌患者的， IPO—38在早期胃癌甚至癌前病变阶段的诊断价值尚不清楚。目前，该课题组已着手开展这方面研究。（生物谷Bioon.com）

生物谷推荐原始出处：

J Proteome Res，7 (9), 3668–3677，Yuan Hao，Zhenggang Zhu

IPO-38 Is Identified as a Novel Serum Biomarker of Gastric Cancer Based on Clinical Proteomics Technology

Yuan Hao,?# Yingyan Yu,*? Lishun Wang,?# Min Yan,? Jun Ji,? Ying Qu,? Jun Zhang,? Bingya Liu,? and Zhenggang Zhu

Gastric cancer is one of the most common malignancies in China. So far, there are few reliable serum biomarkers for diagnosis. The available biomarkers of CEA, CA19–9 and CA72–4 are not sufficiently sensitive and specific for gastric cancer. In this study, a high density antibody microarray was used for identifying new biomarkers from serum samples of gastric cancer. Serum samples from colorectal cancer, pancreatic cancer, hepatocellular cancer, and breast cancer were also screened for comparative study. As result, some candidate biomarkers were identified. IPO-38, an up-regulated serum protein in gastric cancer was selected for subsequent validation including serum IPO-38 expression by ELISA and IPO-38 protein expression by immunohistochemistry. The immunoprecipitation by IPO-38 for gastric cancer cell line and MALDI-TOF/TOF mass spectrometer suggested that pull-down of IPO-38 belongs to H2B histone, which was supported by co-localization study of laser scanning confocal microscope. A follow-up study showed that the survival rate of IPO-38 negative group was better than that in IPO-38 positive group. The study first clarified the property of IPO-38 proliferating marker, and proposed that IPO-38 protein is a promising biomarker both for diagnosis and for predicting prognosis of gastric cancer.